Advertisement

Advertisement

ESMO Congress 2022

Solid Tumors

Practice-Changing Studies, Important New Data, and More Clinical Oncology News From ESMO 2022, Paris

The European Society For Medical Oncology (ESMO) launched its annual congress, held September 9–13, 2022, just as this issue of The ASCO Post was going to press. Watch upcoming issues for comprehensiv...

colorectal cancer
immunotherapy

Julien Taïeb, MD, PhD, on Colorectal Cancer: Recent Findings on Avelumab vs Standard Second-Line Chemotherapy

Julien Taïeb, MD, PhD, of Paris Descartes University, discusses phase II results from the SAMCO-PRODIGE 54 trial, which shows the efficacy and safety of avelumab in the second-line treatment of patien...

kidney cancer

Nizar M. Tannir, MD, on RCC: Data on Bempegaldesleukin Plus Nivolumab vs Tyrosine Kinase Inhibitors in Untreated Disease

Nizar M. Tannir, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the PIVOT-09 study, which compared bempegaldesleukin plus nivolumab with the investigator’s...

Bladder Cancer
Immunotherapy

New Research From Cohort K of the EV-103 Trial of Enfortumab Vedotin for Patients With Urothelial Cancer

Researchers from Memorial Sloan Kettering (MSK) Cancer Center shared data on a treatment option for patients with bladder cancer at the European Society for Medical Oncology (ESMO) Congress 2022 (Abst...

lung cancer

Tony S.K. Mok, MD, on NSCLC: Review of Recent Data From the SUNRISE and ORIENT-31 Trials

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses two late-breaking abstracts presented at ESMO 2022: the phase II SUNRISE study, which compared sintilimab plus anlotinib vs platinu...

breast cancer
survivorship

Matteo Lambertini, MD, PhD, on Oncofertility Care for Young Women With Breast Cancer

Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, talks about why oncofertility counseling should now be considered mandatory in the care of young women wit...

skin cancer
immunotherapy

Georgina V. Long, MD, PhD, on Melanoma: Findings on Circulating Tumor DNA, Disease Recurrence, and Immunotherapy

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, discusses results from the CheckMate 915 trial, an analysis of the pretreatment circulating tumor DNA, along with other clinical and tr...

skin cancer

Neil D. Gross, MD, on Cutaneous Squamous Cell Carcinoma: Recent Findings on Cemiplimab

Neil D. Gross, MD, of The University of Texas MD Anderson Cancer Center, discusses data from a phase II study, which showed that neoadjuvant cemiplimab-rwlc in patients with stage II–IV (M0) resectabl...

lung cancer
immunotherapy

Gérard Zalcman, MD, PhD, on Non–Small Cell Lung Cancer: Phase III Trial Findings on Nivolumab and Ipilimumab

Gérard Zalcman, MD, PhD, of France’s Bichat-Claude Bernard Hospital, Assistance Publique–Hôpitaux de Paris, discusses phase III results from the IFCT-1701 trial, which explored the questions of whethe...

head and neck cancer
immunotherapy

Jean-Pascal Machiels, MD, PhD, on Head and Neck Cancer: Recent Data on Pembrolizumab and Chemoradiation Therapy

Jean-Pascal Machiels, MD, PhD, of Belgium’s Cliniques universitaires Saint-Luc (UCLouvain), discusses the primary results of the phase III KEYNOTE-412 study of pembrolizumab plus chemoradiation therap...

prostate cancer

Neal D. Shore, MD, on Prostate Cancer: Biomarker Analysis, Enzalutamide, and Active Surveillance

Neal D. Shore, MD, of Carolina Urologic Research Center/Genesis Care, discusses new data from the ENACT trial, which showed that patients with prostate cancer and the RNA biomarkers PAM50 and AR-A wer...

Kidney Cancer
Immunotherapy

Adjuvant Atezolizumab Does Not Improve Disease-Free Survival in Patients With RCC

Adjuvant therapy with the anti–PD-L1 therapy atezolizumab failed to improve disease-free survival compared to placebo in patients with renal cell carcinoma (RCC) at high risk of recurrence after resec...

Lung Cancer
Genomics/Genetics

Updated Results From the ADAURA Trial of Adjuvant Osimertinib in EGFR-Mutated NSCLC

Newly released results from the phase III ADAURA trial revealed that osimertinib yielded a 5.5-year median disease-free survival in the postsurgical treatment of patients with EGFR-mutated non­–small ...

Skin Cancer
Immunotherapy

Dual Checkpoint Inhibitor Blockade as First-Line or Salvage Therapy for Patients With Advanced Merkel Cell Carcinoma

Merkel cell carcinoma has a high rate of metastasis and poor patient outcomes. The current standard of care for patients with recurrent, unresectable, or metastatic disease is immune checkpoint inhibi...

Colorectal Cancer
Immunotherapy

Early Research Identifies Effective Combination Immunotherapy for Subgroup of Patients With Metastatic Colorectal Cancer

A physician-scientist at City of Hope has identified a novel combination immunotherapy regimen—a triplet therapy consisting of regorafenib, ipilimumab, and nivolumab—that demonstrated significant resp...

kidney cancer
immunotherapy

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Recent Phase III Data on Cabozantinib, Nivolumab, and Ipilimumab From the COSMIC-313 Trial

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss phase III findings showing that cabozantinib in combination ...

kidney cancer
immunotherapy

Axel Bex, MD, PhD, on Renal Cell Carcinoma: Phase III Results With Atezolizumab as Adjuvant Therapy

Axel Bex, MD, PhD, of the Netherlands Cancer Institute, discusses phase III findings from the IMmotion010 study, which evaluated the efficacy and safety of atezolizumab vs placebo in patients with ren...

lung cancer
immunotherapy

Martin Reck, MD, PhD, on NSCLC: New Findings on Cemiplimab, Nivolumab, and Ipilimumab

Martin Reck, MD, PhD, of Germany’s Lung Clinic Grosshansdorf, details two trials that included patients with advanced non–small cell lung cancer: 3-year survival outcomes in the EMPOWER-Lung 1 study o...

hepatobiliary cancer

Richard S. Finn, MD, on Hepatocellular Carcinoma: Recent Data on Lenvatinib Plus Pembrolizumab

Richard S. Finn, MD, of the Geffen School of Medicine at the University of California, Los Angeles, discusses primary phase III results from the LEAP-002 study of pembrolizumab, an anti–PD-1 therapy, ...

kidney cancer

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Review of Two Key Abstracts on Belzutifan Plus Cabozantinib and Pembrolizumab Plus Lenvatinib

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss results from two important trials presented at ESMO 2022: Co...

lung cancer

Charles Swanton, PhD, on Non–Small Cell Lung Cancer Induced by Air Pollution

Charles Swanton, PhD, of The Francis Crick Institute, discusses a newly discovered mechanism of action for air pollution–induced non–small cell lung cancer in which particles linked to climate change ...

Skin Cancer
Immunotherapy

Neodjuvant Cemiplimab in Patients With Stage II to IV Cutaneous Squamous Cell Carcinoma

In an international, multicenter phase II clinical trial, 63.3% of patients with stage II to IV cutaneous squamous cell carcinoma saw their tumors nearly or completely eradicated when treated with the...

Colorectal Cancer

Updated Results From the KRYSTAL-1 Study of Adagrasib in Advanced KRAS G12C–Mutated Colorectal Cancer

Updated results from KRYSTAL-1, a multicohort phase I/II study, evaluating adagrasib—an investigational, highly selective, and potent oral small-molecule inhibitor of KRAS G12C—with or without cetuxim...

Issues in Oncology

Research Explores Multicancer Early Detection Blood Testing

Physicians, care providers, and payers may be preparing for a major shift in early cancer detection that will affect almost every stage of cancer diagnosis and treatment. New data supporting the accur...

Skin Cancer
Immunotherapy

SWOG S1801: Neoadjuvant and Adjuvant Pembrolizumab for Patients With Stage IIIB to IV Melanoma

Patients with high-risk melanoma who received the anti–PD-1 therapy pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than...

colorectal cancer

Marinde J.G. Bond, PhD Candidate, on Colorectal Liver Metastases: FOLFOX/FOLFIRI, Bevacizumab, and Panitumumab

Marinde J.G. Bond, PhD Candidate, of the University Medical Center, Utrecht, discusses phase III findings from the CAIRO5 study of the Dutch Colorectal Cancer Group, the first such trial in defined su...

skin cancer
immunotherapy

Sapna P. Patel, MD, on Melanoma: New Data on Pembrolizumab, Adjuvant vs Neoadjuvant Plus Adjuvant

Sapna P. Patel, MD, of The University of Texas MD Anderson Cancer Center, discusses the latest findings from the SWOG S1801 trial, which showed that using single-agent pembrolizumab as neoadjuvant the...

breast cancer
genomics/genetics

Antonio Marra, MD, on Metastatic Breast Cancer: Patterns of Genomic Instability and Their Effect on Treatment

Antonio Marra, MD, of Memorial Sloan Kettering Cancer Center, discusses a mutational signature analysis that reveals patterns of genomic instability linked to resistance to endocrine therapy with or w...

gynecologic cancers
immunotherapy

Ana Oaknin, MD, PhD, on Cervical Cancer: Safety and Efficacy Results With Nivolumab and Ipilimumab

Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses findings from the CheckMate 358 trial, which showed that chemotherapy-free immunotherapy with nivolumab alone or in com...

gynecologic cancers

Ana Oaknin, MD, PhD, on Cervical Cancer: New Findings on Cemiplimab in Recurrent or Metastatic Disease

Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses an analysis of long-term survival from the EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. Cemiplimab-rwlc is the first im...

pancreatic cancer

Christelle de la Fouchardiere, MD, on Pancreatic Ductal Adenocarcinoma: Phase III Trial Results With Gemcitabine Plus Paclitaxel

Christelle de la Fouchardiere, MD, of France’s Centre Léon Bérard, discusses phase III findings from the PRODIGE 65–UCGI 36–GEMPAX UNICANCER study, which evaluated whether the combination of gemcitabi...

solid tumors

Bernd Kasper, MD, PhD, on Desmoid Tumors: Results on Nirogacestat vs Placebo

Bernd Kasper, MD, PhD, of Germany’s Mannheim Cancer Center, discusses phase III data from the DeFi trial, the largest study conducted to date for patients with desmoid tumors. The trial showed that th...

gynecologic cancers

Paul A. DiSilvestro, MD, on Ovarian Cancer: New Data on Olaparib in Newly Diagnosed Disease

Paul A. DiSilvestro, MD, of Women & Infants Hospital and the Warren Alpert Medical School of Brown University, discusses overall survival results after a 7-year follow-up of the SOLO1/GOG-3004 tr...

Prostate Cancer

PRESTO: Treatment Beyond Androgen-Deprivation Therapy for Relapsed Patients With High-Risk Prostate Cancer

Aggarwal et al presented data from PRESTO (AFT-19) at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA63), the first trial to evaluate whether intensifying treatment beyond...

Breast Cancer

TROPiCS-02 Update: Sacituzumab Govitecan Improves Overall Survival in Previously Treated Patients With Hormone Receptor–Positive, HER2-Negative Breast Cancer

An overall survival benefit has now emerged for sacituzumab govitecan-hziy in patients with previously treated hormone receptor–positive/HER2-negative locally recurrent inoperable or metastatic breast...

Breast Cancer

T-DXd for Patients With HER2-Low Metastatic Breast Cancer: Patient-Reported Outcomes

Patients who received trastuzumab deruxtecan (T-DXd) for HER2-low metastatic breast cancer reported that the treatment maintained their quality of life compared to conventional chemotherapy, according...

Skin Cancer

M14TIL: Tumor-Infiltrating Lymphocytes for Patients With Advanced Melanoma

A novel treatment strategy with personalized cell therapy significantly improved progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to results f...

Solid Tumors

Nirogacestat for Progressive Desmoid Tumors: DeFi Trial

Significant improvements in progression-free survival and response rate—combined with reduced symptoms and better quality of life—were reported as outcomes of a new treatment approach for patients wit...

Kidney Cancer
Immunotherapy

COSMIC-313: Cabozantinib, Nivolumab, and Ipilimumab in Previously Untreated Patients With Advanced Renal Cell Carcinoma

A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by Toni K. Chouei...

Kidney Cancer
Immunotherapy

PROSPER RCC: Neoadjuvant Nivolumab Prior to Nephrectomy Followed by Additional Nivolumab in Patients With Renal Cell Carcinoma

The ECOG-ACRIN Cancer Research Group presented data from PROSPER RCC (EA8143), the first randomized phase III trial of neoadjuvant immunotherapy in patients with kidney cancer, at the European Society...

Lung Cancer
Genomics/Genetics

Researchers Examine How Air Pollution May Drive Lung Cancer in Never-Smokers

A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and the...

Global Cancer Care

ESMO and EONS Announce Launch of PrEvCan

On September 9, the European Society for Medical Oncology (ESMO), together with the European Oncology Nursing Society (EONS), announced the launch of the Europe-wide “Cancer Prevention Across Europe” ...

Advertisement

Advertisement



Advertisement